Tuesday, February 25, 2020

Genome Editing/Genome Engineering Market to Witness an Outstanding Growth During 2019-2030 - Thermo Fisher Scientific, Lonza, Merck

Genome Editing/Genome Engineering technique are used for insertion, deletion or modify genome of a microorganism. Techniques like TALEN, CRISPR (clustered regularly interspaced palindromic repeat) and other technique are widely used in genome editing/engineering process. CRISPR-Cas9 technique is one of the most widely preferred technologies in genome editing. The global genome editing/genome engineering market is driven by technological advancements in the genomics, rising number of cancer patients, and increasing funding by government & private players in the genomics are major factors driving the market. However, ethical issue related to genome editing/genome engineering is likely to restrain the market to certain extent.

Market Industry Reports (MIR) has published a new report titled "Genome Editing/Genome Engeineering Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2030." According to the report the global genome editing market was valued at over US$ 3.0 Bn. in 2017 and is anticipated to grow at a CAGR of 14.1% from 2019 to 2030.

Major Key Players of the Genome Editing/Genome Engineering Market are:
Thermo Fisher Scientific, Lonza, Merck, Horizon Discovery Group, Integrated DNA Technologies, New England Biolabs (US), GenScript (US), Sangamo BioSciences (US), OriGene Technologies (US), Transposagen Biopharmaceuticals (US), Editas Medicine (US), and CRISPR Therapeutics (Switzerland)., among others.

Read More @ http://www.sbwire.com/press-releases/genome-editinggenome-engineering-market-to-witness-an-outstanding-growth-during-2019-2030-thermo-fisher-scientific-lonza-merck-1279000.htm


Strong product pipeline are anticipated to impact the industrial growth over the forecast period of 2019–2030. The novel products are designed to help in development of DNA targeting, with improved flexibility, specificity of nuclease, and the ease of Adeno-Associate Virus (AAV) packaging for delivery. Moreover, utilization of the technique through a number of methods such as disruption of viral DNA, correction in the toxic mutations, or the addition of therapeutic transgenes is projected to boost the adoption.

Application of the technology for cell line genetic editing or engineering in the form of gene therapy and stem cell therapy accounted for the considerable share and is estimated to register lucrative growth. Furthermore, use of the genome editing technology for the development of novel molecules which can be targeted for treating various diseases such as infectious diseases and hematological malignancies is likely to drive the adoption of the technology in the coming years.


No comments:

Post a Comment